Diamyd Medical’s CEO comments on the recent approval by FDA of Provention Bio´s drug candidate Teplizumab

“The FDA approval of teplizumab is great news for the entire autoimmune diabetes field,” comments Ulf Hannelius, CEO of Diamyd Medical. “The approval creates clarity around the regulatory pathway for disease-modifying therapies in Type 1 Diabetes and will set a reference for the field regarding pricing and reimbursement. This is important and valuable for the antigen-specific immunotherapy Diamyd[®], the first ever precision medicine therapeutic for Type 1 Diabetes in Phase 3 development.“ Provention Bio’s drug Teplizumab is a CD3-directed monoclonal antibody expected to be given as a